Prediagnostic plasma IGFBP‐1, IGF‐1 and risk of prostate cancer |
| |
| Authors: | Yin Cao Katharina Nimptsch Irene M. Shui Elizabeth A. Platz Kana Wu Michael N. Pollak Stacey A. Kenfield Meir J. Stampfer Edward L. Giovannucci |
| |
| Affiliation: | 1. Department of Nutrition, Harvard School of Public Health, Boston, MA;2. Max Delbrück Center for Molecular Medicine (MDC), Molecular Epidemiology Research Group, Berlin, Germany;3. Department of Epidemiology, Harvard School of Public Health, Boston, MA;4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;5. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD;6. The Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD;7. Departments of Medicine and Oncology, Lady Davis Research Institute of the Jewish General Hospital and McGill University, Montreal, QC, Canada;8. Department of Urology, University of California, San Francisco, San Francisco, CA;9. Channing Division of Network Medicine, Brigham Women's Hospital and Harvard Medical School, Boston, MA |
| |
| Abstract: | Insulin‐like growth factor (IGF)?1 is associated with a higher risk of prostate cancer. IGF‐binding protein (IGFBP)?1, a marker for insulin activity, also binds IGF‐1 and inhibits its action. Data on IGFBP‐1 and prostate cancer risk are sparse and whether the IGF and insulin axes interact to affect prostate cancer carcinogenesis is unknown. We evaluated the independent and joint influence of prediagnostic plasma levels of IGFBP‐1 (fasting) and IGF‐1 on risk of prostate cancer among 957 cases and 1,021 controls with fasting levels of IGFBP‐1 and 1,709 cases and 1,778 controls with IGF‐1 nested within the Health Professionals Follow‐up Study. Unconditional logistic regression adjusting for matching factors was used to estimate the odds ratio (OR) and 95% confidence interval (CI). Higher prediagnostic fasting IGFBP‐1 levels were associated with lower risk of prostate cancer (highest vs. lowest quartile OR = 0.67, 95% CI 0.52–0.86, ptrend = 0.003), which remained similar after adjusting for IGF‐1. Prediagnostic IGF‐1 was associated with increased risk of prostate cancer (highest vs. lowest quartile OR = 1.28, 95% CI = 1.05–1.56, ptrend = 0.01). The associations with each marker were primarily driven by lower‐grade and non‐advanced prostate cancer. Being low in IGFBP‐1 and high in IGF‐1 did not confer appreciable additional risk (pinteraction = 0.42). In summary, prediagnostic fasting IGFBP‐1 may influence prostate cancer carcinogenesis. Being low in IGFBP‐1 or high in IGF‐1 is sufficient to elevate the risk of prostate cancer. |
| |
| Keywords: | IGFBP‐1 IGF‐1 insulin prostate cancer risk |
|
|
